Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) had its price objective cut by Royal Bank Of Canada from $25.00 to $21.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Royal Bank Of Canada's price objective suggests a potential upside of 95.80% from the stock's current price.
Several other research firms have also weighed in on NTLA. Guggenheim reduced their price objective on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Chardan Capital reiterated a "buy" rating and issued a $68.00 price objective on shares of Intellia Therapeutics in a report on Friday, May 9th. Canaccord Genuity Group lowered their price objective on shares of Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating on the stock in a report on Tuesday, June 3rd. Wolfe Research upgraded shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price objective on the stock in a report on Monday, April 21st. Finally, HC Wainwright lowered their price objective on shares of Intellia Therapeutics from $30.00 to $25.00 and set a "buy" rating on the stock in a report on Friday. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $31.11.
Get Our Latest Stock Analysis on NTLA
Intellia Therapeutics Price Performance
Shares of NASDAQ NTLA traded down $0.74 during trading hours on Friday, hitting $10.73. 2,357,273 shares of the stock were exchanged, compared to its average volume of 4,046,047. The company's 50 day moving average is $10.47 and its 200 day moving average is $9.50. The firm has a market capitalization of $1.11 billion, a P/E ratio of -2.05 and a beta of 2.31. Intellia Therapeutics has a one year low of $5.90 and a one year high of $24.16.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.03) by $0.04. Intellia Therapeutics had a negative net margin of 1,154.10% and a negative return on equity of 56.06%. The company had revenue of $14.25 million during the quarter, compared to analysts' expectations of $12.26 million. During the same quarter in the prior year, the company posted ($1.52) EPS. The business's revenue was up 104.3% on a year-over-year basis. Research analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 7,462 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total transaction of $104,617.24. Following the completion of the sale, the executive vice president directly owned 106,062 shares of the company's stock, valued at approximately $1,486,989.24. This trade represents a 6.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders sold 12,534 shares of company stock worth $153,837. 3.10% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Intellia Therapeutics
Hedge funds have recently bought and sold shares of the stock. Ensign Peak Advisors Inc raised its stake in Intellia Therapeutics by 2.9% during the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company's stock valued at $457,000 after purchasing an additional 1,100 shares during the period. HighTower Advisors LLC raised its stake in Intellia Therapeutics by 8.2% during the 1st quarter. HighTower Advisors LLC now owns 16,921 shares of the company's stock valued at $120,000 after purchasing an additional 1,282 shares during the period. Harbour Investments Inc. raised its stake in Intellia Therapeutics by 27.2% during the 2nd quarter. Harbour Investments Inc. now owns 6,633 shares of the company's stock valued at $62,000 after purchasing an additional 1,419 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in Intellia Therapeutics by 56.4% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock valued at $33,000 after purchasing an additional 1,655 shares during the period. Finally, Virtus ETF Advisers LLC raised its stake in Intellia Therapeutics by 47.7% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,242 shares of the company's stock valued at $61,000 after purchasing an additional 1,692 shares during the period. Hedge funds and other institutional investors own 88.77% of the company's stock.
Intellia Therapeutics Company Profile
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.